Xenon Pharmaceuticals Inc
XP0
Company Profile
Business description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Contact
200-3650 Gilmore Way
BurnabyBCV5G 4W8
CANT: +1 604 484-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
370
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
stocks
Undervalued ASX share upgrades guidance
Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,032.80 | 0.50 | 0.01% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,415.98 | 208.80 | 0.83% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 61,965.34 | 2,965.85 | -4.57% |
| NZX 50 Index | 13,847.13 | 3.56 | -0.03% |
| S&P 500 | 7,413.18 | 1.20 | 0.02% |
| S&P/ASX 200 | 8,865.60 | 3.40 | 0.04% |
| SSE Composite Index | 3,830.75 | 27.50 | -0.71% |